Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2085

Sort by

Sort Order Select

Journal Articles

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Blood (2021) 138 (14): 1258–1268.

https://doi.org/10.1182/blood.2020010331

Published: 2021

Includes: Supplemental data

Journal Articles

Introduction to a review series on gene therapy and gene editing for sickle cell disease and hemophilia

Catherine M. Bollard

Blood (2021) 138 (11): 913.

https://doi.org/10.1182/blood.2021012891

Published: 2021

Journal Articles

Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues

Frank W. G. Leebeek, Wolfgang Miesbach

Blood (2021) 138 (11): 923–931.

https://doi.org/10.1182/blood.2019003777

Published: 2021

Journal Articles

Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect

Kaushik Das, Shiva Keshava, Shabbir A. Ansari, Vijay Kondreddy, Charles T. Esmon, John H. Griffin, Usha R. Pendurthi, L. Vijaya Mohan Rao

Blood (2021) 137 (24): 3428–3442.

https://doi.org/10.1182/blood.2020008417

Published: 2021

Includes: Supplemental data

Journal Articles

Structure of blood coagulation factor VIII in complex with an anti–C1 domain pathogenic antibody inhibitor

Joseph S. Gish, Lexi Jarvis, Kenneth C. Childers, Shaun C. Peters, Connor S. Garrels, Ian W. Smith, H. Trent Spencer, Christopher B. Doering, Pete Lollar, P. Clint Spiegel, Jr

Blood (2021) 137 (21): 2981–2986.

https://doi.org/10.1182/blood.2020008940

Published: 2021

Includes: Supplemental data

Journal Articles

Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy

James R. Fuller, Kevin E. Knockenhauer, Nina C. Leksa, Robert T. Peters, Joseph D. Batchelor

Blood (2021) 137 (21): 2970–2980.

https://doi.org/10.1182/blood.2020009197

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

Activated protein C has a regulatory role in factor VIII function

Amelia R. Wilhelm, Nicole A. Parsons, Benjamin J. Samelson-Jones, Robert J. Davidson, Charles T. Esmon, Rodney M. Camire, Lindsey A. George

Blood (2021) 137 (18): 2532–2543.

https://doi.org/10.1182/blood.2020007562

Published: 2021

Includes: Supplemental data

Journal Articles

von Willebrand disease: what does the future hold?

Cécile V. Denis, Sophie Susen, Peter J. Lenting

Blood (2021) 137 (17): 2299–2306.

https://doi.org/10.1182/blood.2020008501

Published: 2021

Journal Articles

In hemophilia, it just keeps getting better

Aric Parnes

Blood (2021) 137 (16): 2135–2136.

https://doi.org/10.1182/blood.2020010238

Published: 2021

Journal Articles

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Blood (2021) 137 (16): 2231–2242.

https://doi.org/10.1182/blood.2020009217

Published: 2021

Includes: Supplemental data

Journal Articles

Prophylaxis in hemophilia: how much is enough?

Christine L. Kempton

Blood (2021) 137 (13): 1709–1711.

https://doi.org/10.1182/blood.2020009603

Published: 2021

Journal Articles

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Robert Klamroth, Jerzy Windyga, Vlad Radulescu, Peter W. Collins, Oleksandra Stasyshyn, Hishamshah Mohd Ibrahim, Werner Engl, Srilatha D. Tangada, William Savage, Bruce Ewenstein

Blood (2021) 137 (13): 1818–1827.

https://doi.org/10.1182/blood.2020005673

Published: 2021

Includes: Supplemental data

Journal Articles

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

Nadine Vollack-Hesse, Olga Oleshko, Sonja Werwitzke, Barbara Solecka-Witulska, Christoph Kannicht, Andreas Tiede

Blood (2021) 137 (8): 1072–1081.

https://doi.org/10.1182/blood.2020006468

Published: 2021

Includes: Supplemental data

Journal Articles

No CpGs for AAVs?

Lindsey A. George

Blood (2021) 137 (6): 721–723.

https://doi.org/10.1182/blood.2020009285

Published: 2021

Journal Articles

A hemophilia A mouse model for the in vivo assessment of emicizumab function

Stephen Ferrière, Ivan Peyron, Olivier D. Christophe, Charlotte Kawecki, Caterina Casari, Vincent Muczynski, Amit Nathwani, Alexandre Kauskot, Peter J. Lenting, Cécile V. Denis

Blood (2020) 136 (6): 740–748.

https://doi.org/10.1182/blood.2019004334

Published: 2020

Includes: Supplemental data

Journal Articles

How much clotting is enough?

Laurent O. Mosnier

Blood (2020) 136 (6): 651–652.

https://doi.org/10.1182/blood.2020006443

Published: 2020

Journal Articles

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Jhansi Magisetty, Usha R. Pendurthi, Charles T. Esmon, L. Vijaya Mohan Rao

Blood (2020) 135 (25): 2211–2223.

https://doi.org/10.1182/blood.2019003824

Published: 2020

Includes: Supplemental data

Journal Articles

Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum

Juthakorn Poothong, Anita Pottekat, Marina Siirin, Alexandre Rosa Campos, Adrienne W. Paton, James C. Paton, Jacqueline Lagunas-Acosta, Zhouji Chen, Mark Swift, Niels Volkmann, Dorit Hanein, Jing Yong, Randal J. Kaufman

Blood (2020) 135 (21): 1899–1911.

https://doi.org/10.1182/blood.2019002867

Published: 2020

Includes: Supplemental data

Journal Articles

A molecular jewel for hemophilia A treatment

Julie Rayes, Sébastien Lacroix-Desmazes

Blood (2020) 135 (17): 1417–1419.

https://doi.org/10.1182/blood.2020005250

Published: 2020

Journal Articles

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Blood (2020) 135 (17): 1484–1496.

https://doi.org/10.1182/blood.2019001292

Published: 2020

Includes: Supplemental data

NARROW

A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice

Introduction to a review series on gene therapy and gene editing for sickle cell disease and hemophilia

Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues

Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect

Structure of blood coagulation factor VIII in complex with an anti–C1 domain pathogenic antibody inhibitor

Molecular determinants of the factor VIII/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy

Activated protein C has a regulatory role in factor VIII function

von Willebrand disease: what does the future hold?

In hemophilia, it just keeps getting better

Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies

Prophylaxis in hemophilia: how much is enough?

Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study

Recombinant VWF fragments improve bioavailability of subcutaneous factor VIII in hemophilia A mice

No CpGs for AAVs?

A hemophilia A mouse model for the in vivo assessment of emicizumab function

How much clotting is enough?

EPCR deficiency or function-blocking antibody protects against joint bleeding–induced pathology in hemophilia mice

Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum

A molecular jewel for hemophilia A treatment

BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only